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The extent ofphosphorylation of9-(2-hydroxyethoxymethyl)guanine (acyclovir
[ACV]) in fresh peripheral leukocytes, in Epstein-Barr virus (EBV)-infected
lymphoblastoid cell lines, and in herpes simplex virus type 1-infected lympho-
blastoid (P3HR-1) and monkey kidney (Vero) cells was determined by high-
pressure liquid chromatography. Mono-, di-, and triphosphorylated derivatives of
[8-14C]ACV were detected at low levels at various times after superinfection of
Raji cells with EBV. The extent of phosphorylation appeared to be related to the
concentration of ACV in the medium. Small amounts of ACV mono-, di-, and
triphosphates were formed in fresh peripheral leukocyte preparations from EBV-
seropositive and -seronegative donors. Comparable ACV monophosphate levels
were detected in EBV-negative BJAB and the EBV-positive BJAB/GC cell lines;
however, no di- or triphosphate derivatives were detected. Comparable ACV-
monophosphate levels were detected in both P3HR-1 and HSV-infected P3HR-1
cell lines; however, larger amounts of ACV di- and triphosphorylated derivatives
were detected in the HSV-infected P3HR-1 cells. ACV was converted to the
triphosphate to a greater extent in HSV-infected Vero cells than in mock-infected
Vero cells or in HSV-infected P3HR-1 cells. ACV or its phosphorylated derivatives
were converted to guanine nucleotides to a greater extent in lymphoblastoid cells
than in fibroblasts (Vero). In conclusion, neither the productive replication of
EBV nor the presence of latent viral DNA is required for ACV monophosphate
formation in B lymphoblastoid cells. ACV triphosphate, however, was detected
only in cells infected productively with EBV.
The nucleoside analog 9-(2-hydroxyethoxy-
methyl)guanine (acyclovir [ACV]), a potent an-
tiherpetic compound in herpes simplex virus
(HSV)-infected cells, requires phosphorylation
to be effective. ACV monophosphate is formed
in HSV-infected cells by viral thymidine kinase
(8, 12) and is subsequently converted to the di-
and triphosphorylated forms (8) by enzymes not
fully characterized. Recent studies indicate that
cellular GMP kinase is responsible for the con-
version of ACV monophosphate to the diphos-
phate (15). The triphosphate derivative of ACV
inhibits the HSV-induced DNA polymerase in
vitro to a greater extent than it inhibits the a
DNA polymerase of the host cell (8, 11).
ACV is also an effective inhibitor of DNA
replication of another herpesvirus, the Epstein-
Barr virus (EBV) (5). The drug has little cyto-
toxicity for lymphoblastoid cells at concentra-
tions necessary for complete inhibition of EBV
DNA synthesis (5). The triphosphate form of
the drug has been shown to inhibit the EBV
DNA polymerase in vitro to a much greater
degree than it does host DNA polymerases (7).
Despite conflicting reports of the induction of a
new thymidine kinase activity in EBV-infected
lymphoblastoid cells (2, 3), there is no evidence
that EBV induces in these cells a thymidine
kinase activity like that induced in HSV-infected
fibroblasts.
We report here the extent of phosphorylation
of ACV in fresh peripheral human leukocytes
and in EBV-infected and mock-infected lympho-
blastoid cell lines. Because EBV does not infect
fibroblast cell lines, a direct comparison of the
extent of phosphorylation of ACV in HSV and
EBV-infected fibroblasts is not possible. How-
ever, a continuous HSV-producing P3HR-1 cell
line has been established (18) which is infected
persistently with HSV; it is called P3HR-
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1(MAL). A majority of the HSV-infected P3HR-
1 cells produce HSV antigens, and a small num-
ber actively produce the virus (18). Selective
phosphorylation, particularly triphosphoryla-
tion, of ACV occurs in HSV-infected fibroblast
cell lines (8, 11, 12). Because a relatively small
amount of di- and triphosphates of ACV were
detected in P3HR-1 cells, tests were performed
to determine whether infection of P3HR-1 cells
with HSV enhances the ability of the EBV-pro-
ducing cells to forn ACV phosphates.
MATERIALS AND METHODS
Compounds. The [8-'4C]ACV, synthesized in the
Burroughs Wellcome Co. laboratories by Jeffrey
Scharver (unpublished data), had a specific activity of
52.6 mCi/mmol.
Cell cultures and virus. The continuous cell lines
P3HR-1 (13), Raji (9, 10, 17), BJAB (14), and BJAB/
GC (4) were maintained between 2 x 105 and 106 cells
per ml at 370C in RPMI 1640 medium supplemented
with 10% fetal calf serum and antibiotics (100 U of
penicillin and 100 ug of streptomycin per ml).
Fresh peripheral blood leukocytes from normal do-
nors 1 (without antibodies to EBV) and 2 (with anti-
bodies to EBV) were derived by the Ficoll-Hypaque
method (1).
P3HR-1 cells persistently infected with the MAL
strain of HSV-1 (passage 24), P3HR-1 control cells
(passage 24), and the MAL strain of HSV-1 (kindly
provided by W. G. Robey) have been described pre-
viously (18). Stocks of HSV-1(MAL) were prepared in
Vero cell cultures and stored at -70°C.
Vero cells were grown in Eagle minimal essential
medium supplemented with 10% fetal calf serum and
antibiotics.
Virus agsay. HSV-1(MAL) titrations were per-
formed in Vero cell cultures as described previously
(6).
Preparation of P3EHR-1 virus and superinfec-
tion of Raji cells. EBV for superinfection was pre-
pared from P3HR-1 cells as described (19).
For superinfection, a total of 1.2 x 108 Raji cells
were pelleted and either mock infected (6 x 107 cells)
or infected (6 x 107 cells) with 3 ml of the virus
suspension (time zero). After 1 h at 370C, the cells
were pelleted, resuspended in 10 ml of fresh RPMI
1640 medium supplemented with 10% fetal calf serum,
and incubated in a C02 incubator at 370C. At 2, 4, 6,
10, 15, and 20 h postinfection, 107 mock-infected and
107 superinfected Raji cells were pelleted, washed with
fresh medium, and suspended in 10 ml of medium
containing ['4C]ACV at concentrations of 25 or 250
jIM. The cells were incubated for 4 h, and then pelleted
and washed three times with phosphate-buffered sa-
line solution (130 mM NaCl, 5 mM KCI, and 0.01 M
sodium phosphate, pH 7.4). Cell pellets to be analyzed
for nucleotide content were quick-frozen with acetone-
dry ice before extraction with perchloric acid.
Treatment of celi cultures with [14C]ACV.
P3HR-1, Raji, BJAB, and BJAB/GC cells were di-
luted to 5 x 105 cells per ml with fresh RPMI 1640
medium and incubated at 370C for 24 h before 4-h
treatment with 250 yIM [14C]ACV.
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Fresh peripheral blood leukocytes were exposed for
4 h to 250 ,uM [14C]ACV in RPMI 1640 medium
supplemented with 10% fetal calf serum after separa-
tion from heparinized whole blood.
P3HR-1 control cells and HSV-infected P3HR-1
cells were subcultured in fresh RPMI 1640 medium
supplemented with 10% fetal calfserum and antibiotics
9 days before 4-h treatment with 250 ILM ['4C]ACV.
Vero cells were infected with HSV-1(MAL) at a mul-
tiplicity of infection of 10. At 1 h after infection, the
medium (10 ml) was replaced by medium containing
150 ,uM [14C]ACV, and the mixture was incubated at
370C for 6 h.
After treatment with [14C]ACV, cells were pelleted
and washed three times with phosphate-buffered sa-
line. Cell pellets to be analyzed for nucleotide content
were quick-frozen with acetone-dry ice.
Nucleotide analysis by high-pressure liquid
chromatography. Perchloric acid cell extracts were
prepared and assayed for ACV mono-, di-, and tri-
phosphates by high-pressure liquid chromatography
as described previously (8).
RESULTS
Kinetics of ACV phosphorylation in su-
perinfected Raji cells. Superinfection of Raji
cells with EBV leads to suppression of cellular
DNA synthesis, to fragmentation of cellular
DNA, and to replication of EBV DNA (16, 19,
20). The biological activity of the P3HR-1 EBV
preparation used in these studies was assayed
by buoyant density analysis ofDNA synthesized
after superinfection. A cesium chloride buoyant
density profile of DNA labeled during superin-
fection of Raji cells is shown in Fig. 1. Most of
the DNA synthesized during infection was viral
(p = 1.718 g/cm3), with little host DNA synthe-
sized (p = 1.700 g/cm3).
The time course of phosphorylation of ACV
in superinfected Raji cells was examined. Raji
cells infected with the P3HR-1 strain of EBV
and exposed to 25 or 250 ,uM [14C]ACV were
analyzed for ACV phosphates at various times
after infection (Tables 1 and 2). ACV mono-
phosphate was detected in both superinfected
and mock-infected Raji cells treated with 25 ,uM
ACV; however, no di- or triphosphorylated de-
rivatives ofACV were detected in mock-infected
cells or superinfected cells (with a single excep-
tion) exposed to 25 ,sM ACV (Table 1). The
extent of formation of ACV mono-, di-, and
triphosphates in superinfected Raji cells was
related to the concentration of ACV in the me-
dium (Tables 1 and 2).
ACV mono-, di-, and triphosphates were de-
tected in superinfected Raji cells exposed to a
10-fold higher concentration (250 ,uM) of ACV
(Table 2). Between 6 and 10 h, the level of ACV
monophosphate increased in both superinfected
and mock-infected Raji cells; resuspension in
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FIG. 1. Neutral cesium chloride density profile of
[32P]DNA synthesized during superinfection without
ACV. The arrow indicates the position of 1.718 g/
cm3, the position of EBV DNA. A total of 106 Raji
cells were pelleted and suspended in 0.3 ml of virus
suspension at time zero. After 1 h at 37°C, the cells
were pelleted, washed twice, and suspended in 1 ml
ofphosphate-free medium (minimal essential medium
minus phosphate and containing 2%o dialyzed fetal
calf serum). At 9 h postinfection, 200 ,iCi of 32p was
added, and incubation was continued for 24 h.
TABLE 1. Kinetics ofphosphorylation ofACV in
superinfected Raji cells treated with 25 jMACV
ACV phosphorylated deriva-
Time tives (pmol per 106 cells)a
Rajicells postin-
Raji cells fection Mono- Diph Trh
(hr' pphaote phate phate
Superinfectedb 2 2.16 <0.03 <0.03
4 1.40 <0.03 <0.03
6 2.26 <0.03 <0.03
10 2.21 <0.03 <0.03
15 2.25 <0.03 0.15
20 1.34 <0.03 <0.03
Mock infectedb 2 1.84 <0.03 <0.03
4 2.14 <0.03 <0.03
6 0.54 <0.03 <0.03
10 1.09 <0.03 <0.03
15 2.25 <0.03 <0.03
20 0.78 <0.03 <0.03
aAt various times postinfection, 25 FiM [8-'4C]ACV
was added for 4 h before nucleotide analysis by high-
pressure liquid chromatography.
b Raji ce1Ls were mock infected or superinfected with
P3HR-1-derived EBV.
fresh medium may be responsible for this in-
crease. ACV di- and triphosphates were detected
in superinfected Raji cells as early as 4 h post-
infection. However, no ACV triphosphate was
TABLE 2. Kinetics ofphosphorylation ofACV in
superinfected Raji cells treated with 250 1LMACV
ACV phosphorylated deriva-
Time tives (pmol per 106 cells)a
Raji cells postin-
fection Mono- D Tphs
(h)a phos- Diphos Triphos
phate phate phate
Superinfectedb 2 5.24 <0.03 <0.03
4 4.40 <0.03 0.32
6 2.20 0.31 0.17
10 9.60 0.30 0.30
15 4.80 0.15 0.13
20 3.70 0.20 0.24
Mock infectedb 2 1.12 <0.03 <0.03
4 1.80 <0.03 <0.03
6 1.05 <0.03 <0.03
10 11.20 0.16 <0.03
15 10.80 <0.03 <0.03
20 9.00 0.09 <0.03
a various times postinfection, 250 ,uM [8-14C]ACV
was added for 4 h before nucleotide analysis by high-
pressure liquid chromatography.
b Raji cells were mock infected or superinfected with
P3HR-1-derived EBV.
detected in mock-infected Raji cells. The lower
limit of detectability ofACV phosphates in these
studies varied between 0.01 and 0.03 pmol of
ACV phosphates per 106 cells.
Phosphorylation of ACV in fresh periph-
eral leukocytes and in EBV genome-nega-
tive and EBV genome-positive lymphoblas-
toid cell lines. To determine whether cells with
and without EBV differ in their capacity to
phosphorylate ACV, the extent of phosphoryla-
tion was measured in the following cell types:
BJAB cells (a Burkitt lymphoma line lacking
EBV DNA), BJAB/GC cells (an EBV-converted
BJAB subline), and freshly prepared peripheral
leukocytes from EBV-seronegative and -sero-
positive donors.
Small quantities of ACV mono-, di-, and tri-
phosphate derivatives were detected in fresh
peripheral leukocyte preparations (Table 3).
Monophosphate levels were also detected in
BJAB and BJAB/GC cell lines; however no di-
or triphosphate derivatives were detected in
these lines. Differences in ACV di- and triphos-
phate levels in peripheral leukocytes and in lym-
phoblastoid cell lines may be attributable to the
fact that freshly prepared leukocytes represent
a mixed population of cells, whereas BJAB and
BJAB/GC cell lines are comprised only of B
lymphocytes (4, 14). These studies suggest that
phosphorylation ofACV by established lympho-
blastoid cell lines is not a characteristic acquired
necessarily during in vitro cell culture.
Metabolism of ACV in P3HR-1 and HSV-
infected P3HR-1 cell lines. The extent of
phosphorylation of ACV was measured in
J. VIROL.
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TABLE 3. Phosphorylation ofACV in leukocytes
from EB V-seronegative and -positive peripheral
donors and in EBVgenome-negative and -positive
lymphoblastoid cells





Donor la 1.15 0.08 0.16
Donor 2a 1.89 0.08 0.24
BJABb 2.25 <0.03 <0.03
BJAB/GCb 1.60 <0.03 <0.03
a Fresh peripheral blood leukocyte populations from
normal donors 1 (without antibodies to EBV) and 2
(with antibodies to EBV). Cells were exposed to 250
ILM [14C]ACV.
b BJAB, a Burkitt lymphoma cell line which lacks
EBV, and BJAB/GC, an EBV-converted subline. Cells
were exposed to 250 ,uM ['4C]ACV.
P3HR-1 and in HSV-infected P3HR-1 cell lines
to determine whether infection with HSV alters
the capacity oflymphoblastoid cells to phospho-
rylate ACV.
A previous investigation demonstrated that
ACV is phosphorylated in Vero cells infected by
the H-29 and MacIntrye strains of HSV-1 (8);
this study shows that Vero cells infected with
the MAL strain of HSV-1 also phosphorylate
ACV (Table 4).
At the time of analyses for ACV phosphoryl-
ation, P3HR-1 cells and HSV-infected P3HR-1
celLs produced an average HSV titer of 0 and 9.4
x 10 PFU/ml (106 cells per ml), respectively;
the percentage of viable cells (measured by eosin
exclusion) in both cultures was greater than 96%.
Comparable ACV monophosphate levels were
detected in both P3HR-1 and HSV-infected
P3HR-1 cell lines; however, greater quantities of
ACV di- and triphosphorylated derivatives were
detected in the HSV-infected P3HR-1 cells (Ta-
ble 4). The degree of phosphorylation ofACV to
the triphosphate in HSV-infected Vero cells was
considerably greater than that in HSV-infected
P3HR-1 cells (Table 4).
During the examination of high-pressure liq-
uid chromatography profiles of extracts of
P3HR-1 and HSV-infected P3HR-1 cells ex-
posed to [14C]ACV, radioactivity was detected
in the elution positions corresponding to GMP,
GDP, and GTP (Table 5). These quantities were
higher than the quantities of [14C]GMP,
[14C]GDP, and [14C]GTP formed in HSV-in-
fected Vero celLs. Raji cells, whether superin-
fected with EBV or not, showed a degree of
formation of [14C]guanine nucleotides from
[14C]ACV that was intermediate between that of
Vero cells and P3HR-1 cells. Whether the re-
moval of the acyclic side chain occurs on ACV
TABLE 4. ACV nucleotides formed in Vero, HSV-
infected Vero, P3HR-1, and HSV-infected P3HR-1
cells
ACV phosphorylated derivatives




Vero <0.01 1.23 1.40
Vero (HSV)a 1.20 4.90 42.40
P3HR-1 6.70 <0.03 0.08
P3HR-1 (HSV)b 5.00 1.10 2.10
a Vero cells were infected with HSV-1(MAL) with
a multiplicity of infection of 10. Cells were exposed to
150 'M [14C]ACV.b P3HR-1 celLs were persistently infected with HSV-
1(MAL) (18). CelLs were exposed to 250 ,uM [14C]ACV.
TABLE 5. [14C]guanine nucleotides derived from
[14CIACV in Vero and P3HR-1 cells
['4C]guanine nucleotides (pmol per
Cell type 10 cells)
GMP GDP GTP
Vero (HSV)a 3.6 3.3 19.0
P3HR-lb 38.0 106.0 154.0
P3HR-1 (HSV)b 20.0 54.0 146.0
Raji
Mock infectedb NDC 40.0 76.0
Superinfectedb ND 75.0 59.0
a Cells were exposed to 150 ,uM [14C]ACV for 6 h.
b Cells were exposed to 250 ,uM [14C]ACV for 4 h.
c ND, Not determined.
itself or on one of its phosphorylated derivatives
is unknown at present. It appears that lympho-
blastoid cells (P3HR-1) have a greater capacity
to alter ACV or its phosphorylated derivatives
than do fibroblasts (Vero).
DISCUSSION
ACV has little cytotoxicity for non-virus-pro-
ducing lymphoblastoid cells which carry EBV
DNA in a latent state as episomes, and the drug
has no apparent effect on the replication of the
viral DNA in these cells (5). ACV is, however,
an effective inhibitor of EBV DNA replication
in productively infected lymphoblastoid cells. At
100 IAM, ACV inhibits completely EBV DNA
synthesis in superinfected Raji cells and reduces
the average number of EBV genomes in P3HR-
1 cultures to a maxrimum of 14 per cell. The
ACV-resistant EBV genomes remaining in
P3HR-1 cultures are covalently closed circular
DNA molecules which are presumed to be rep-
licated-by the host DNA polymerases rather
than the EBV DNA polymerase (5).
ACV triphosphate inhibits the activity of pu-
rified EBV DNA polymerase in vitro (7), and
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presumably this effect occurs in EBV-infected
cells. The selective inhibitory action of ACV
triphosphate in vitro on EBV DNA synthesis,
but not on cellular DNA synthesis, is reflected
in the greater affinity of the EBV DNA polym-
erase for ACV triphosphate than for the cellular
a DNA polymerase; the affinity of the EBV
DNA polymerase for ACV triphosphate (Ki =
0.015 ± 0.002 J.M) is approximately a hundred
times greater than that for the cellular a polym-
erase (Ki = 1.500 ± 0.050 ,M) (7). These previous
studies indicate that phosphorylation of ACV is
essential for inhibition of viral DNA synthesis in
EBV-infected cells.
The study reported here shows that ACV
mono-, di-, and triphosphates are formed in hu-
man B-lymphoblastoid cells. ACV monophos-
phate formation, however, requires neither pro-
ductive infection with EBV nor the presence of
latent EBV genomes, as both EBV genome-neg-
ative and positive B-lymphoblastoid cells (Raji,
superinfected Raji, P3HR-1, BJAB, and BJAB/
GC) converted ACV to the monophosphate.
ACV monophosphate was readily detectable in
both Raji and superinfected Raji cells exposed
to 25 ,uM ACV (Table 1), a concentration which
is fourfold less than that necessary for complete
inhibition of EBV DNA synthesis in superin-
fected Raji cells. It is unlikely that B-lympho-
blastoid cells acquired the capacity to form ACV
monophosphate as a result of long-term growth
in cell culture because freshly prepared periph-
eral leukocytes from human donors (EBV sero-
negative and seropositive) also phosphorylated
the drug (Table 3).
Di- and triphosphorylated derivatives of the
drug were not detected consistently in cells ex-
posed to 25 ,uM ACV (Table 1). However, when
the concentration of ACV in the medium was
increased (250 ,uM), ACV di- and triphosphates
were detected consistently, but only in superin-
fected Raji cells (Table 2). The increased levels
of ACV di- and triphosphates in lymphoblastoid
cells can be attributed to productive infection.
ACV phosphates are also found at higher
levels in HSV-infected fibroblasts than in mock-
infected cells (Vero), where these phosphoryla-
tions occur to a limited extent (8) (Table 4).
Phosphorylation of ACV in the HSV system is
attributable to the presence of HSV-specified
pyrimnidine deoxynucleoside (thymidine) kinase
activity which is expressed in HSV-infected fi-
broblasts and converts ACV to the monophos-
phate (8). ACV monophosphate is subsequently
converted to ACV di- and triphosphates.
The inefficient phosphorylation of ACV in
lymphoblastoid cells is not simply due to their
lymphoblastoid nature, inasmuch as our data
show that infection of P3HR-1 cells with HSV
increased the level of ACV triphosphate by 30-
fold (Table 4). Cellular extracts prepared from
HSV-infected P3HR-1 cells phosphorylate ACV
in vitro, and this phosphorylation is inhibited by
excess thymidine (J. Fyfe, personal communi-
cation). These observations suggest that the
HSV-specific thymidine kinase is expressed in
these cells after infection with HSV. The levels
of ACV di- and triphosphates, although in-
creased in HSV-infected lymphoblastoid cells,
are lower than those formed in HSV-infected
fibroblasts. This result could be attributable to
the fact that all Vero cells are infected, whereas
a lower number of lymphoblastoid cells are in-
fected with HSV (18). The lower levels of ACV
phosphates formed in B-lymphoblastoid cell
lines may also be related to the increased capac-
ity of these cells to alter ACV or its phosphoryl-
ated derivatives (Table 5).
Despite the lower levels of ACV phosphates
in lymphoblastoid cells, the concentration of
ACV triphosphate in superinfected Raji cells, as
well as in P3HR-1 cells which are infected pro-
ductively with EBV, was sufficient to inhibit
EBV DNA polymerase activity. The range of
ACV triphosphate concentrations per superin-
fected Raji cell was approximately 0.034 to 0.064
,uM; these concentrations are at least twofold
higher than the Ki values reported for the EBV
DNA polymerase in vitro (7). These determi-
nations are based on a packed cell volume of 106
cells per 5 p1 and on the triphosphate data for
superinfected Raji cells (Table 2).
This work demonstrates that ACV is phos-
phorylated to the triphosphate in EBV-infected
lymphoblastoid cells; these data are consistent
with the hypothesis that phosphorylation of the
drug is necessary for inhibition of viral DNA
synthesis in these cells. The enzymes which
phosphorylate ACV in EBV-infected lympho-
blastoid cells have not been identified. It is un-
likely, however, that the enzyme(s) responsible
for formation of ACV monophosphate in EBV-
infected cells is a pyrimidine deoxynucleoside
(thymidine) kinase with electromobility charac-
teristics of HSV thymidine kinase. In this re-
spect, the enzymes which phosphorylate ACV in
the EBV and HSV systems may differ. The
formation ofACV phosphates in lymphoblastoid
cells may be related to the induction of host
enzymatic activity during replication of EBV. It
is interesting that EBV genome-negative cell
lines and EBV-seronegative peripheral leuko-
cytes also formed ACV phosphates; these data
indicate that the enzymes which convert the
drug to its phosphates are of cellular origin. A
phosphorylating enzyme other than a thymidine
J. VIROL.
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kinase may be responsible for formation ofACV
monophosphate in EBV-infected cells.
The degree of sensitivity of the different
herpes group viruses to ACV probably depends
on various factors. Among these factors are the
degree of sensitivity of the viral DNA polymer-
ase to ACV triphosphate, the degree of phos-
phorylation ofACV, which is dependent on both
virus-induced and host enzymatic activities, and
the extent to which ACV or its phosphorylated
derivatives are altered in infected cells. The last
two factors are interrelated and underline the
fact that the sensitivity of herpesviruses to ACV,
as shown in this work and work with HSV (8,
11), is related to cell type.
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